Merck Companies manufactured prescription drug, Fosamax, which is made in tablet form and prescribed to thwart osteoporosis in post-menopausal women. Fosamax is classified in a class of drugs called bisphosphonates, which is “the class of drugs that prevent the loss of bone mass and is used to treat osteoporosis and similar diseases”. Fosamax puts many women at risk due to side effects that could cause a serious bone disease called osteonecrosis of the Jaw (ONJ). “Osteonecrosis is a disfiguring and disabling condition of the jaw bone that cause infection and rotting of the jaw bone”. Symptoms of Osteonecrosis include, but are not limited to-pain, soft-tissue swelling and infection, loosening of teeth, drainage, and exposed bone. Symptoms of Fosamax “may occur spontaneously, or at the site of previous tooth extraction”.